Kimberly Cooper, MS

Assessment of Health-Related Quality of Life and Health Status in Patients With Treatment Resistant Depression Treated With Esketamine Nasal Spray Plus Oral Antidepressant Using European Quality of Life Group-5-Dimension-5-Level

Objective: To assess health-related quality of life (HRQoL) and health status of patients with treatment resistant depression (TRD), treated with esketamine nasal spray+oral antidepressan...

Vanina Popova , MD;

Ella Daly , MB, BCh, BAO;

Kimberly Cooper , MS;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

11/22/2019

Determining Meaningful Change in Depression Symptoms Assessed With the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) Among Patients With Treatment Resistant Depression in Trials of Esketamine Nasal Spray

Introduction: Meaningful change thresholds (MCT) derived from clinical outcome assessments quantify the change amount during pharmacologic treatment that is meaningful to the patient. We ...

Carol Jamieson , BSc;

Stacie Hudgens , MA, MSc;

Vanina Popova , MD;

Kimberly Cooper , MS;

Wayne Drevets , MD;

Maggie Fedgchin , PharmD;

Jaskaran Singh , MD;

Lysbeth Floden , PhD;

Rosanne Lane , MD, MSc, MS;

11/22/2019

Evaluation of Depression Severity Items on the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) in Patients With Treatment-Resistant Depression Treated With Esketamine Nasal Spray

Introduction: Major depressive disorder is a leading cause of disability and about 30% of patients are diagnosed with treatment-resistant depression (TRD) after failing two pharmacologica...

Lysbeth Floden , PhD;

Vanina Popova , MD;

Stacie Hudgens , MA, MSc;

Kimberly Cooper , MS;

Wayne Drevets , MD;

Jaskaran Singh , MD;

Carol Jamieson , BSc;

11/22/2019